$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000109355715000242 Filed on August 05, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$93.20M	$58.80M
YoY Change	58.5%	64.25%
Cost Of Revenue	$27.20M	$18.90M
YoY Change	43.92%	35.97%
Gross Profit	$66.00M	$39.90M
YoY Change	65.41%	82.19%
Gross Profit Margin	70.82%	67.86%
Selling, General & Admin	$45.20M	$30.90M
YoY Change	46.28%	49.28%
% of Gross Profit	68.48%	77.44%
Research & Development	$24.40M	$14.80M
YoY Change	64.86%	33.33%
% of Gross Profit	36.97%	37.09%
Depreciation & Amortization	$2.600M	$1.900M
YoY Change	36.84%	18.75%
% of Gross Profit	3.94%	4.76%
Operating Expenses	$69.60M	$45.70M
YoY Change	52.3%	43.71%
Operating Profit	-$3.600M	-$5.800M
YoY Change	-37.93%	-41.41%
Interest Expense	$100.0K	$200.0K
YoY Change	-50.0%	0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$3.700M	-$6.000M
YoY Change	-38.33%	-40.59%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.700M	-$6.000M
YoY Change	-38.33%	-40.59%
Net Earnings / Revenue	-3.97%	-10.2%
Basic Earnings Per Share
Diluted Earnings Per Share	-$46.48K	-$80.00K
COMMON SHARES
Basic Shares Outstanding	79.60M shares	75.00M shares
Diluted Shares Outstanding	79.60M shares	75.30M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$97.50M	$61.30M
YoY Change	59.05%	32.11%
Cash & Equivalents	$67.70M	$49.50M
Short-Term Investments	$29.80M	$11.80M
Other Short-Term Assets	$5.000M	$4.000M
YoY Change	25.0%	42.86%
Inventory	$22.40M	$11.60M
Prepaid Expenses
Receivables	$45.50M	$28.60M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$170.4M	$105.5M
YoY Change	61.52%	42.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.60M	$26.00M
YoY Change	56.15%	36.13%
Goodwill	$3.700M	$3.200M
YoY Change	15.63%	0.0%
Intangibles	$2.500M	$3.300M
YoY Change	-24.24%	-15.38%
Long-Term Investments
YoY Change
Other Assets	$500.0K	$700.0K
YoY Change	-28.57%	-22.22%
Total Long-Term Assets	$48.00M	$34.20M
YoY Change	40.35%	21.71%
TOTAL ASSETS
Total Short-Term Assets	$170.4M	$105.5M
Total Long-Term Assets	$48.00M	$34.20M
Total Assets	$218.4M	$139.7M
YoY Change	56.34%	36.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.70M	$7.000M
YoY Change	67.14%	150.0%
Accrued Expenses	$29.30M	$26.00M
YoY Change	12.69%	58.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.400M	$2.300M
YoY Change	4.35%	91.67%
Total Short-Term Liabilities	$44.20M	$35.60M
YoY Change	24.16%	68.72%
LONG-TERM LIABILITIES
Long-Term Debt	$1.100M	$3.500M
YoY Change	-68.57%	-39.66%
Other Long-Term Liabilities	$2.400M	$1.000M
YoY Change	140.0%	-67.74%
Total Long-Term Liabilities	$2.400M	$1.000M
YoY Change	140.0%	-67.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.20M	$35.60M
Total Long-Term Liabilities	$2.400M	$1.000M
Total Liabilities	$47.70M	$40.10M
YoY Change	18.95%	33.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$514.4M	-$493.9M
YoY Change	4.15%	5.81%
Common Stock	$685.3M	$593.6M
YoY Change	15.45%	10.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$170.7M	$99.60M
YoY Change
Total Liabilities & Shareholders Equity	$218.4M	$139.7M
YoY Change	56.34%	36.56%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$3.700M	-$6.000M
YoY Change	-38.33%	-40.59%
Depreciation, Depletion And Amortization	$2.600M	$1.900M
YoY Change	36.84%	18.75%
Cash From Operating Activities	$16.40M	$6.200M
YoY Change	164.52%	588.89%
INVESTING ACTIVITIES
Capital Expenditures	-$6.300M	-$4.000M
YoY Change	57.5%	100.0%
Acquisitions
YoY Change
Other Investing Activities	-$900.0K	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$7.200M	-$4.000M
YoY Change	80.0%	-165.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.300M	1.600M
YoY Change	168.75%	-30.43%
NET CHANGE
Cash From Operating Activities	16.40M	6.200M
Cash From Investing Activities	-7.200M	-4.000M
Cash From Financing Activities	4.300M	1.600M
Net Change In Cash	13.50M	3.800M
YoY Change	255.26%	-59.14%
FREE CASH FLOW
Cash From Operating Activities	$16.40M	$6.200M
Capital Expenditures	-$6.300M	-$4.000M
Free Cash Flow	$22.70M	$10.20M
YoY Change	122.55%	251.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	9200000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1100000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1200000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	80081542	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
	dei	Trading Symbol TradingSymbol	DXCM
CY2014Q4	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	42400000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3800000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5000000	USD
CY2015Q2	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	45500000	USD
CY2014Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1600000	USD
CY2015Q2	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1800000	USD
CY2014Q4	dxcm	Clinical Trials ClinicalTrials	400000	USD
CY2015Q2	dxcm	Clinical Trials ClinicalTrials	300000	USD
CY2012Q4	dxcm	Debt Instrument Basis Spread On Treasury Variable Rate DebtInstrumentBasisSpreadOnTreasuryVariableRate	0.0694
CY2014Q2	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	200000	USD
	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	600000	USD
CY2015Q2	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	0	USD
	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	0	USD
CY2014Q2	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	600000	USD
	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	1000000	USD
CY2015Q2	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	300000	USD
	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	300000	USD
	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	200000	USD
	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	0	USD
CY2014Q2	dxcm	Markto Marketon Contingent Consideration Obligation Settleablein Shares MarktoMarketonContingentConsiderationObligationSettleableinShares	-1000000	USD
	dxcm	Markto Marketon Contingent Consideration Obligation Settleablein Shares MarktoMarketonContingentConsiderationObligationSettleableinShares	0	USD
CY2015Q2	dxcm	Markto Marketon Contingent Consideration Obligation Settleablein Shares MarktoMarketonContingentConsiderationObligationSettleableinShares	0	USD
	dxcm	Markto Marketon Contingent Consideration Obligation Settleablein Shares MarktoMarketonContingentConsiderationObligationSettleableinShares	0	USD
	dxcm	Potential Rental Rate Adjustment Maximum PotentialRentalRateAdjustmentMaximum	0.04
	dxcm	Potential Rental Rate Adjustment Minimum PotentialRentalRateAdjustmentMinimum	0.025
CY2012Q4	dxcm	Prime Rate Plus PrimeRatePlus	0.005
	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
CY2013	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	500000	USD
CY2014	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	2500000	USD
	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	1000000	USD
CY2013Q3	dxcm	Researchand Development Arrangement Valueof Grant ResearchandDevelopmentArrangementValueofGrant	4000000	USD
	dxcm	Sales Return Coverage Period SalesReturnCoveragePeriod	P30D
CY2012Q4	dxcm	Term Loan Advances Aggregate Amount TermLoanAdvancesAggregateAmount	7000000	USD
CY2012Q4	dxcm	Term Loan Debt TermLoanDebt	20000000	USD
CY2015Q2	dxcm	Working Capital WorkingCapital	126200000	USD
CY2014Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	20400000	USD
CY2015Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	24000000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9900000	USD
CY2015Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	11700000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-200000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-300000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	638000000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	685300000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	200000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	100000	USD
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9100000	shares
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6500000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6500000	shares
CY2014Q4	us-gaap	Assets Assets	184600000	USD
CY2015Q2	us-gaap	Assets Assets	218400000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	145900000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	170400000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11800000	USD
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	29800000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11800000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29800000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43200000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49500000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71800000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67700000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6300000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4100000	USD
CY2015Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	97500000	USD
CY2014Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	54300000	USD
CY2015Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	31300000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77600000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80300000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77300000	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80000000	shares
CY2014Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2015Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18500000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3700000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16800000	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	18700000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	35600000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	27200000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	53500000	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	18900000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	36200000	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	27200000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	53500000	USD
CY2012Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-11-01
CY2015Q2	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	15000000	USD
CY2012Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	13000000	USD
CY2012	us-gaap	Debt Issuance Costs DebtIssuanceCosts	1100000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	700000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	800000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17200000	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17000000	USD
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	177500000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-200000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	3700000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	39900000	USD
	us-gaap	Gross Profit GrossProfit	69700000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	66000000	USD
	us-gaap	Gross Profit GrossProfit	112500000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.08
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.25
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.21
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.09
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.25
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.21
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4400000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3700000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2500000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3100000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-400000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	100000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2000000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-200000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2600000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6400000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-200000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	900000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	600000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1000000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-300000	USD
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	300000	shares
	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2700000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2500000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	200000	USD
	us-gaap	Interest Expense InterestExpense	400000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	100000	USD
	us-gaap	Interest Expense InterestExpense	300000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7400000	USD
CY2015Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12600000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	16000000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	22400000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7600000	USD
CY2015Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9100000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1000000	USD
CY2015Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	700000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	44400000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	47700000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	184600000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	218400000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40600000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	44200000	USD
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	15000000	USD
CY2015Q2	us-gaap	Long Term Debt LongTermDebt	3500000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1200000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2300000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10800000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9200000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8300000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33100000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3800000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19800000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-6000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18500000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-3700000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16600000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18500000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3700000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16600000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	45700000	USD
	us-gaap	Operating Expenses OperatingExpenses	87800000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	69600000	USD
	us-gaap	Operating Expenses OperatingExpenses	128800000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5800000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18100000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3600000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16300000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	32500000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1900000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	5200000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4100000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4500000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	11800000	USD
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	800000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1500000	USD
CY2015Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1400000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2700000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8500000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10200000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	600000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	500000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-200000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1500000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2400000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	6400000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	27500000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7900000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14300000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3900000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11900000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10400000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	6000000	USD
CY2014Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1100000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	2200000	USD
CY2015Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1700000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3100000	USD
CY2015Q2	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	30200000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31200000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40600000	USD
CY2014Q2	us-gaap	Revenues Revenues	58800000	USD
	us-gaap	Revenues Revenues	105900000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14800000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29300000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24400000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44200000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	700000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	700000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-497800000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-514400000	USD
CY2015Q2	us-gaap	Revenues Revenues	93200000	USD
	us-gaap	Revenues Revenues	166000000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	58200000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	104900000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	92900000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	165700000	USD
CY2014Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2300000	USD
CY2015Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	2400000	USD
CY2014Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2300000	USD
CY2015Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1100000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30900000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58500000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45200000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	84600000	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	13200000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21900000	USD
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	20700000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	36600000	USD
CY2013Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	900000	USD
CY2014Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	800000	USD
CY2014Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	900000	USD
CY2014Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1300000	USD
CY2015Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1100000	USD
CY2015Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1200000	USD
CY2014Q2	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1200000	USD
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	2200000	USD
CY2015Q2	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1800000	USD
	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	3000000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	140200000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	170700000	USD
CY2015Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	100000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75300000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74200000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78700000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79600000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75000000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74200000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79600000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78700000	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of</font><font style="font-family:inherit;font-size:10pt;"> continuous glucose monitoring (“CGM”)</font><font style="font-family:inherit;font-size:10pt;"> systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with </font><font style="font-family:inherit;font-size:10pt;">U.S. GAAP</font><font style="font-family:inherit;font-size:10pt;"> requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, employee bonus, clinical trial expenses, allowance for bad debt, and share-based compensation expense. </font></div></div>

Files In Submission

Name	View Source	Status
0001093557-15-000242-index-headers.html	Edgar Link	pending
0001093557-15-000242-index.html	Edgar Link	pending
0001093557-15-000242.txt	Edgar Link	pending
0001093557-15-000242-xbrl.zip	Edgar Link	pending
dxcm-06302015x10q.htm	Edgar Link	pending
dxcm-20150630.xml	Edgar Link	completed
dxcm-20150630.xsd	Edgar Link	pending
dxcm-20150630_cal.xml	Edgar Link	unprocessable
dxcm-20150630_def.xml	Edgar Link	unprocessable
dxcm-20150630_lab.xml	Edgar Link	unprocessable
dxcm-20150630_pre.xml	Edgar Link	unprocessable
dxcm06302015ex3101.htm	Edgar Link	pending
dxcm06302015ex3102.htm	Edgar Link	pending
dxcm06302015ex3201.htm	Edgar Link	pending
dxcm06302015ex3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2015 Q2 Form 10-Q Financial Statement

#000109355715000242 Filed on August 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2015 Q2 Form 10-Q Financial Statement

#000109355715000242 Filed on August 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm